721 related articles for article (PubMed ID: 34126044)
1. Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases: an open-label, multicentre, randomised, controlled, phase 2/3 trial.
Sahgal A; Myrehaug SD; Siva S; Masucci GL; Maralani PJ; Brundage M; Butler J; Chow E; Fehlings MG; Foote M; Gabos Z; Greenspoon J; Kerba M; Lee Y; Liu M; Liu SK; Thibault I; Wong RK; Hum M; Ding K; Parulekar WR;
Lancet Oncol; 2021 Jul; 22(7):1023-1033. PubMed ID: 34126044
[TBL] [Abstract][Full Text] [Related]
2. Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial.
Chow E; van der Linden YM; Roos D; Hartsell WF; Hoskin P; Wu JS; Brundage MD; Nabid A; Tissing-Tan CJ; Oei B; Babington S; Demas WF; Wilson CF; Meyer RM; Chen BE; Wong RK
Lancet Oncol; 2014 Feb; 15(2):164-71. PubMed ID: 24369114
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Ball D; Mai GT; Vinod S; Babington S; Ruben J; Kron T; Chesson B; Herschtal A; Vanevski M; Rezo A; Elder C; Skala M; Wirth A; Wheeler G; Lim A; Shaw M; Schofield P; Irving L; Solomon B;
Lancet Oncol; 2019 Apr; 20(4):494-503. PubMed ID: 30770291
[TBL] [Abstract][Full Text] [Related]
4. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
[TBL] [Abstract][Full Text] [Related]
5. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial.
Brown PD; Ballman KV; Cerhan JH; Anderson SK; Carrero XW; Whitton AC; Greenspoon J; Parney IF; Laack NNI; Ashman JB; Bahary JP; Hadjipanayis CG; Urbanic JJ; Barker FG; Farace E; Khuntia D; Giannini C; Buckner JC; Galanis E; Roberge D
Lancet Oncol; 2017 Aug; 18(8):1049-1060. PubMed ID: 28687377
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
Altorki NK; McGraw TE; Borczuk AC; Saxena A; Port JL; Stiles BM; Lee BE; Sanfilippo NJ; Scheff RJ; Pua BB; Gruden JF; Christos PJ; Spinelli C; Gakuria J; Uppal M; Binder B; Elemento O; Ballman KV; Formenti SC
Lancet Oncol; 2021 Jun; 22(6):824-835. PubMed ID: 34015311
[TBL] [Abstract][Full Text] [Related]
7. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
[TBL] [Abstract][Full Text] [Related]
8. Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases-A Phase 2 Randomized Controlled Trial Within a Prospective Cohort.
Pielkenrood BJ; van der Velden JM; van der Linden YM; Bartels MMT; Kasperts N; Verhoeff JJC; Eppinga WSC; Gal R; Verlaan JJ; Verkooijen HML
Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):358-367. PubMed ID: 33333200
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
Palma DA; Olson R; Harrow S; Gaede S; Louie AV; Haasbeek C; Mulroy L; Lock M; Rodrigues GB; Yaremko BP; Schellenberg D; Ahmad B; Griffioen G; Senthi S; Swaminath A; Kopek N; Liu M; Moore K; Currie S; Bauman GS; Warner A; Senan S
Lancet; 2019 May; 393(10185):2051-2058. PubMed ID: 30982687
[TBL] [Abstract][Full Text] [Related]
10. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2019 Feb; 20(2):267-281. PubMed ID: 30579763
[TBL] [Abstract][Full Text] [Related]
11. Fractionated radiosurgery for painful spinal metastases: DOSIS - a phase II trial.
Guckenberger M; Hawkins M; Flentje M; Sweeney RA
BMC Cancer; 2012 Nov; 12():530. PubMed ID: 23164174
[TBL] [Abstract][Full Text] [Related]
12. Dose-intensified hypofractionated stereotactic body radiation therapy for painful spinal metastases: Results of a phase 2 study.
Guckenberger M; Sweeney RA; Hawkins M; Belderbos J; Andratschke N; Ahmed M; Madani I; Mantel F; Steigerwald S; Flentje M
Cancer; 2018 May; 124(9):2001-2009. PubMed ID: 29499073
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Body Radiotherapy for Spinal Metastases: Clinical Experience in 134 Cases From a Single Japanese Institution.
Ito K; Ogawa H; Shimizuguchi T; Nihei K; Furuya T; Tanaka H; Karasawa K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806472. PubMed ID: 30355246
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy.
Sprave T; Verma V; Förster R; Schlampp I; Bruckner T; Bostel T; Welte SE; Tonndorf-Martini E; Nicolay NH; Debus J; Rief H
Radiother Oncol; 2018 Aug; 128(2):274-282. PubMed ID: 29843899
[TBL] [Abstract][Full Text] [Related]
15. A prospective multicentre feasibility study of stereotactic body radiotherapy in Japanese patients with spinal metastases.
Ito K; Furuya T; Shikama N; Nihei K; Tanaka H; Kumazaki Y; Nishimura H; Karasawa K
Jpn J Clin Oncol; 2019 Dec; 49(11):999-1003. PubMed ID: 31665478
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
[TBL] [Abstract][Full Text] [Related]
17. Local response and pathologic fractures following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy for spinal metastases - a randomized controlled trial.
Sprave T; Verma V; Förster R; Schlampp I; Hees K; Bruckner T; Bostel T; El Shafie RA; Welzel T; Nicolay NH; Debus J; Rief H
BMC Cancer; 2018 Aug; 18(1):859. PubMed ID: 30170568
[TBL] [Abstract][Full Text] [Related]
18. A Phase 2 Study of Post-Operative Stereotactic Body Radiation Therapy (SBRT) for Solid Tumor Spine Metastases.
Redmond KJ; Sciubba D; Khan M; Gui C; Lo SL; Gokaslan ZL; Leaf B; Kleinberg L; Grimm J; Ye X; Lim M
Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):261-268. PubMed ID: 31628959
[TBL] [Abstract][Full Text] [Related]
19. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.
Tree AC; Ostler P; van der Voet H; Chu W; Loblaw A; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Armstrong J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Duffton A; Brand DH; Henderson D; Morrison K; Brown S; Pugh J; Burnett S; Mahmud M; Hinder V; Naismith O; Hall E; van As N;
Lancet Oncol; 2022 Oct; 23(10):1308-1320. PubMed ID: 36113498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
